Sagimet Biosciences (Sagimet Biosciences) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sagimet Biosciences's Free Cash Flow for the three months ended in Mar. 2024 was $-6.21 Mil. Sagimet Biosciences's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Sagimet Biosciences's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Sagimet Biosciences's current FCF Yield % is -15.13%.

The historical rank and industry rank for Sagimet Biosciences's FCF Margin % or its related term are showing as below:

SGMT' s FCF Margin % Range Over the Past 10 Years
Min: -1188.3 Med: -1188.3 Max: -1144.5
Current: -1144.5

During the past 5 years, the highest FCF Margin % of Sagimet Biosciences was -1144.50%. The lowest was -1188.30%. And the median was -1188.30%.

SGMT's FCF Margin % is ranked worse than
77.36% of 1047 companies
in the Biotechnology industry
Industry Median: -143.92 vs SGMT: -1144.50

Sagimet Biosciences FCF Margin % Historical Data

The historical data trend for Sagimet Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences FCF Margin % Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-1,188.30

Sagimet Biosciences Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial									-	-	-193.95	-	-

Competitive Comparison of Sagimet Biosciences's FCF Margin %

For the Biotechnology subindustry, Sagimet Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's FCF Margin % falls into.

Sagimet Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sagimet Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-23.766	/	2
	=	-1,188.30 %

Sagimet Biosciences's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-6.208	/	0
	=	%

Sagimet Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences (Sagimet Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (NAS:SGMT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0O2:Germany 0O2:Germany

Address

155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website

https://www.sagimet.com

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Executives

David Happel	director, officer: President & CEO	7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Beth C Seidenberg	director
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth Rozek	officer: General Counsel and CCO	SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO CA 94402
George Kemble	director	SAGIMET BIOSCIENCES INC., 155 BOVET RD., STE. 303, SAN MATEO CA 94402
Jinzi Jason Wu	director	SAGIMET BIOSCIENCES INC., 155 BOVET RD., SUITE 303, SAN MATEO CA 94402
Dennis Hom	officer: Chief Financial Officer	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Kpcb Pbd Associates, Llc	10 percent owner	C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025
Kpcb Pandemic & Bio Defense Fund Llc	10 percent owner	2750 SAND HILL RD, MENLO PARK CA 94025
Eduardo Bruno Martins	director	350 CAMBRIDGE AVE, SUITE 350, PALO ALTO CA 94306
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth A Grammer	director	78TH FOURTH AVENUE, WALTHAM MA 02451
Anthony M Rimac	officer: Chief Operating Officer	C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220, EMERYVILLE CA 94608
Patrick J Kerins	10 percent owner